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Summary
We conducted a large-scale functional genetic study to characterize mechanisms of resistance to 
ALK inhibition in ALK-dependent lung cancer cells. We identify members of known resistance 
pathways and additional putative resistance drivers. Among the latter were members of the P2Y 
purinergic receptor family of G-protein coupled receptors (P2Y1, P2Y2, and P2Y6). P2Y 
receptors mediated resistance in part through a protein kinase C (PKC)-dependent mechanism. 
Moreover, PKC activation alone was sufficient to confer resistance to ALK inhibitors whereas 
combined ALK and PKC inhibition restored sensitivity. We observed enrichment of gene 
signatures associated with several resistance drivers (including P2Y receptors) in crizotinib-
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resistant ALK-rearranged lung tumors compared to treatment-naïve controls, supporting a role for 
identified resistance mechanisms in clinical resistance.
Introduction
An understanding of the mechanisms by which tumors harbor primary drug resistance or 
acquire resistance to targeted therapies is critical for precisely predicting which patients will 
respond to a specific therapy and for the identification of additional targetable pathways to 
maximize clinical benefit (Garraway and Janne, 2012). The EML4-ALK fusion protein is an 
oncogenic driver in a subset of non-small cell lung cancer (NSCLC) (Soda et al., 2007). A 
chromosomal inversion gives rise to EML4-ALK, leading to ectopic expression of 
constitutively-active ALK tyrosine kinase. Aberrant ALK activity in turn up-regulates 
effectors of cell survival and proliferation, including the MEK/ERK and PI3K pathways 
(Shaw et al., 2013).
Crizotinib is an oral MET/ALK inhibitor used as first-line therapy in the treatment of 
advanced NSCLC harboring ALK rearrangements. In addition, newer second-generation 
ALK inhibitors with increased potency and selectivity against ALK are under evaluation in 
clinical trials. Like crizotinib, these agents are ATP-competitive inhibitors of the ALK 
tyrosine kinase although they are structurally distinct from crizotinib. Ceritinib (also known 
as LDK378) is a second-generation inhibitor that has shown remarkable activity in patients 
with ALK-positive lung cancer, including individuals with acquired resistance to crizotinib 
(Shaw et al., 2013; Shaw et al., 2014; Solomon et al., 2014). Ceritinib recently received 
FDA approval for use in patients with advanced ALK-rearranged NSCLC previously treated 
with crizotinib. However, responses to ALK inhibitors are short-lived, with resistance 
commonly occurring within a year.
Since the introduction of crizotinib in the treatment of ALK-driven NSCLC, gene 
amplification or secondary mutations in EML4-ALK have been identified in approximately 
one-third of tumors with acquired resistance to crizotinib (Choi et al., 2010; Doebele et al., 
2012; Katayama et al., 2012; Sasaki et al., 2011). Secondary mutations have been shown in 
vitro to drive resistance to crizotinib, but not all confer resistance to the structurally-distinct 
second-generation ALK inhibitors (Katayama et al., 2011; Katayama et al., 2012). In 
addition, activation of EGFR, KIT, and IGF-1R have been separately identified in a subset 
of tumors with resistance to crizotinib (Katayama et al., 2012; Lovly et al., 2014; Sasaki et 
al., 2011). Resistance to second-generation ALK inhibitors is less characterized due to the 
recent introduction of these agents to the clinic, although secondary mutations in EML4-ALK 
have been identified in a subset of tumors with acquired ceritinib resistance (Friboulet et al., 
2014). Importantly, no mechanism of resistance to crizotinib or ceritinib has been identified 
in up to half of all tumors reported to date (Doebele et al., 2012; Friboulet et al., 2014; 
Katayama et al., 2012). This observation motivates a broad search for additional resistance 
mediators that may provide opportunities for novel therapeutic approaches. We performed a 
large-scale functional genetic study to identify genes whose overexpression is sufficient to 
confer resistance to ALK inhibition.
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A large-scale functional study to identify candidate drivers of resistance to ALK inhibition
We aimed to identify gain-of-function mediators of resistance to ALK inhibition by 
systematic perturbation of gene expression. The Center for Cancer Systems Biology 
(CCSB)-Broad lentiviral expression library is a publicly-available large-scale open reading 
frame (ORF) library consisting of 15,885 ORFs representing 12,800 human genes (Yang et 
al., 2011). To identify transcripts sufficient to drive resistance to ALK inhibition, we 
individually introduced each ORF into an ALK-dependent lung adenocarcinoma cell line 
(H3122) with marked sensitivity to ALK inhibitors. ORF-expressing cells were assayed for 
sensitivity both to crizotinib and to the second-generation ALK inhibitor, TAE684 (Figure 
1A). A mutant form (L1152R) of EML4-ALK known to confer resistance to both crizotinib 
and second-generation ALK inhibitors was used as a positive control (Figure 1B) (Sasaki et 
al., 2011). See Experimental Procedures for a full description of the experimental design.
Statistical analysis of correlation among screening replicates and estimation of lentiviral 
infection efficiency were performed as quality-control measures (Figure S1). 95% of 
assayed ORFs met quality-control thresholds and were evaluated for effects on sensitivity to 
ALK inhibition (see Experimental Procedures). Most ORF-expressing cells remained 
sensitive to crizotinib and TAE684 (Figure 1C). For H3122 cells expressing each individual 
ORF in the library, the differential proliferation in drug was expressed as the ratio of cell 
viability in the presence of drug divided by cell viability in the absence of drug. Differential 
proliferation for each ORF in crizotinib and TAE684 was then expressed as a z-score (% 
viability z-score) to normalize across the entire dataset acquired during the screen (see 
Experimental Procedures). ORFs conferring a differential proliferation in the presence of 
crizotinib or TAE684 ≥3 standard deviations (SD) above the mean (% viability z-score score 
≥3) were selected as candidate mediators of resistance to ALK inhibition. A total of 75 
ORFs representing 67 genes met this criterion, with 43 ORFs yielding a % viability z-score 
≥3 for both drugs (Figure 1D, 2A).
Validation and characterization of candidate drivers of resistance to ALK inhibition in 
H3122
We next performed a validation study in which the 75 candidate ORFs were subjected to 7-
point growth inhibition assays in H3122 with crizotinib and TAE684. The area under the 
curve (AUC) was determined for each ORF. ORFs associated with an AUC ≥2.5 SD above 
the mean for either drug (determined in parallel from a cohort of control ORFs) were 
considered validated resistance drivers in H3122. Overall, 61 ORFs representing 54 genes 
met this criterion (81% of candidate resistance ORFs identified from the initial screening 
study; Figure 2A).
Validated resistance genes reflect diverse protein classes (Figure 2B). Prominent among 
these are transcription factors, serine-threonine and tyrosine kinases, growth factors, and 
signal transduction adapter proteins. Resistance profiles of the 54 validated resistance genes 
against crizotinib and TAE684 in H3122 are shown in Figure 2C. Of note, we confirmed 
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that validated genes also drive resistance to the second-generation ALK inhibitor ceritinib 
with results comparable to TAE684 (Figure S2).
A subset of the identified ALK resistance genes overlap with resistance drivers to MAP 
kinase pathway inhibition identified in BRAF-mutant melanoma (Johannessen et al., 2010; 
Johannessen et al., 2013). Among these are kinases (such as AXL, MAP3K8, and RAF1), 
adapter proteins (including CRKL and GAB1), and transcription factors (such as ETV1, 
FOS, and YAP1). This finding is not surprising given the central role of MEK/ERK 
signaling in both contexts. However there are noteworthy differences between the datasets. 
For example, growth factors are more prevalent in the present study and include five EGF-
related peptides (Figure S2). This is consistent with prior reports suggesting a role for EGF 
ligands and EGFR activation in resistance to ALK inhibition (Katayama et al., 2012; Sasaki 
et al., 2011; Tanimoto et al., 2014; Tanizaki et al., 2012; Voena et al., 2013; Yamada et al., 
2012). More generally, these results corroborate reports implicating paracrine and autocrine 
mechanisms of resistance to targeted therapies (Harbinski et al., 2012; Straussman et al., 
2012; Wilson et al., 2012).
We compared resistance profiles for crizotinib and TAE684 and identified three ORFs 
(AXL, MST1R, and HGF) that validated strongly as drivers of resistance to TAE684 (% 
viability z-score >5.5) but not crizotinib (% viability z-score <1; Figure 2D). This 
discordance likely reflects the pharmacologic activity of crizotinib against AXL, MST1R, 
and MET (the kinase activated by HGF) (Peters and Adjei, 2012). Similar findings for HGF-
mediated resistance to ALK inhibition have been reported (Tanimoto et al., 2014; Yamada et 
al., 2012).
Effects of resistance ORFs on reactivation of MEK/ERK and/or PI3K pathways in H3122
Since oncogenic ALK dysregulation activates the MEK/ERK and PI3K pathways (which 
promote cell proliferation and survival), we next determined whether ectopically expressed 
resistance ORFs might confer resistance by reactivation of ERK and/or AKT in H3122 in 
the presence of TAE684. Approximately half of the resistance ORFs (including a subset of 
growth factors, kinases, and adapter proteins) produced sustained ERK and/or AKT 
activation despite ALK inhibition, underscoring the importance of these pathways in 
mediating ALK-driven tumorigenesis (Figure 3). The remaining resistance ORFs had 
minimal effect on these pathways, raising the possibility of resistance modules that bypass 
these effectors.
Assessment of validated ORFs in resistance to targeted therapies in other NSCLC cell 
systems
To identify resistance mechanisms more broadly operant in ALK-rearranged lung cancer, 
we assayed the 54 validated resistance drivers in MGH006, a second ALK-rearranged 
NSCLC cell line (Sequist et al., 2010). Of these, 23 conferred resistance to ALK inhibition 
in MGH006, as defined by a differential proliferation in drug ≥2.5 SD above the mean 
(determined from control ORFs) with a single dose of crizotinib or TAE684 (Experimental 
Procedures; Figure 4). MGH006 is reported to have a secondary dependence on EGFR 
activation and demonstrates reduced sensitivity to ALK inhibition compared to H3122 
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(Figure S3) (Katayama et al., 2012). This observation, coupled with the finding that ectopic 
ORF expression was generally lower in MGH006 compared to H3122 (Figure S3), suggests 
the resistance effects observed in MGH006 could be an underestimate. Alternatively, our 
findings might indicate that certain molecular contexts enable some resistance mechanisms 
over others.
Several ALK resistance drivers identified in H3122 (including AXL, CRKL, and HGF) have 
previously been implicated in resistance to EGFR inhibitors in EGFR-mutant lung cancer 
(Cheung et al., 2011; Engelman et al., 2007; Zhang et al., 2012). In addition, both the 
MEK/ERK and PI3K pathways are up-regulated by ALK or EGFR activation in lung cancer. 
We hypothesized that a subset of identified mediators of resistance to ALK inhibition in 
H3122 might also drive resistance to EGFR inhibition in EGFR-mutant lung cancer. To test 
this, we expressed the ALK resistance ORFs in three EGFR-mutant NSCLC lines (HCC827, 
HCC4006, and PC-9) and performed inhibition studies with erlotinib (Figure 4, Figure S3). 
Most ORFs mediating ALK resistance in H3122 also conferred resistance to erlotinib in 
EGFR-mutant lines, with 38 of 54 (70%) validating in at least one such line (Experimental 
Procedures). As the activating effects of EGF ligands are presumably blunted by EGFR 
inhibition, no EGF ligands identified from the ALK inhibitor screen induced resistance to 
erlotinib. Together, these results raise the possibility of shared mechanisms of resistance to 
ALK and EGFR inhibition in ALK-rearranged and EGFR-mutant lung cancers, respectively.
We evaluated expression of each resistance ORF in all 5 cell lines assayed in the initial 
screening and subsequent validation studies (Figure S3). The majority of assayed ORFs are 
expressed in all cell systems, although a subset of ORFs demonstrate differential expression 
across cell lines.
Neuregulin-1 as a resistance driver in ALK-dependent lung cancer cell systems
The ORF that most strongly induced resistance to ALK inhibition in both H3122 and 
MGH006 was neuregulin-1 (NRG1), the ligand that activates HER3. Upon ligand binding, 
HER3 forms heterodimers with HER2 to activate downstream signaling pathways. To 
confirm the ORF screening and validation findings for NRG1, we treated ALK-dependent 
cell lines with recombinant NRG1 peptide and assayed resistance to TAE684 (Figure 5A, 
B). Recombinant NRG1 peptide drives resistance to TAE684 in ALK-dependent NSCLC 
cell lines (H3122, H2228, and MGH006). NRG1 had no impact on sensitivity to TAE684 in 
KELLY cells (an ALK-dependent neuroblastoma cell line), suggesting a context-dependent 
role for NRG1 in driving resistance to ALK inhibition. The effect of NRG1 in ALK-
dependent NSCLC cell lines was abrogated with the combination of TAE684 and lapatinib, 
which inhibits the activity of HER2 (the dimerization partner of HER3; Figure 5C, D). 
Together, these findings suggest a role for HER2/HER3 activation in resistance to ALK 
inhibition. Of note, NRG1 has recently been identified as a putative driver alteration in the 
somatic gene fusion CD74-NRG1 in a subset of invasive mucinous lung adenocarcinoma 
(Fernandez-Cuesta et al., 2014).
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Purinergic P2Y receptors as resistance drivers to ALK inhibition in H3122
We also examined less-characterized ALK resistance ORFs and associated pathways. 
Among these is P2Y2 (encoded by P2RY2), a member of the P2Y subfamily of P2 
purinergic receptors. P2Y receptors are membrane-bound G-protein coupled receptors 
(GPCRs) activated in response to extracellular nucleotides including ATP. They are widely-
expressed in a variety of tissues including lung epithelia (Schafer et al., 2003). A role has 
been postulated for P2Y receptors in mediating the activating effects of ATP in the tumor 
microenvironment on tumor growth (Di Virgilio, 2012). However, a role for these proteins 
in drug resistance has not previously been demonstrated. There are multiple P2Y family 
members which are further subdivided based on coupling to either Gq, Gs, or Gi (Baroja-
Mazo et al., 2013). ORFs encoding ten P2Y family members are included in the CCSB-
Broad lentiviral expression library. Strikingly, two additional P2Y family members (P2Y1 
and P2Y6) scored highly in the initial screening study (% viability z-score 2–3) but did not 
meet our threshold for initial follow-up (z-score ≥3; Figure S4).
Given this observation suggesting three P2Y family members capable of impacting 
sensitivity to ALK inhibition in H3122, we examined these GPCRs in further detail. H3122 
cells expressing these P2Y receptors demonstrated a modest but reproducible decrease in 
sensitivity to crizotinib in short-term assays (Figure S4). P2Y-mediated resistance was more 
apparent in colony-formation assays, where we observed increased survival of cells 
expressing P2Y receptors in crizotinib or ceritinib compared to the Lac Z control (most 
notably for P2Y1 and P2Y2; Figure 6A–B).
Resistance associated with P2Y receptors mediated through protein kinase C (PKC)
We sought to explore the mechanism by which P2Y receptors mediate resistance to ALK 
inhibition. Notably, P2Y1, P2Y2, and P2Y6 each couple to Gq to activate phospholipase C 
(Baroja-Mazo et al., 2013). Prior studies suggest that P2Y receptors activate phospholipase 
C and protein kinase C (PKC) (Falkenburger et al., 2013). More specifically, P2Y2 has been 
shown to activate PKCδ in intestinal cells (Amin et al., 2013). Indeed, we found that H3122 
cells overexpressing P2Y1 or P2Y2 (although not P2Y6) had increased levels of activated 
PKCδ (Figure 6C). To determine whether PKC activation alone is sufficient to drive 
resistance to ALK inhibition, we treated H3122 cells with ceritinib in the presence of the 
PKC agonist phorbol 12-myristate 13-acetate (PMA). PMA increased the GI50 of ceritinib 
by 10-fold (Figure 6D). PKC activation also conferred resistance to ceritinib in MGH006 
(Figure 6D). PMA had no impact on basal cell proliferation in the absence of ceritinib 
(Figure 6E). Using activated PKCδ as a marker for PKC activity, we also observed increased 
PKCδ activation in populations of H3122 cells cultured to resistance with ceritinib (in 
addition to increased EGFR activation as previously reported; Figure 6F; Figure S4; 
Experimental Procedures) (Katayama et al., 2012; Sasaki et al., 2011).
Sotrastaurin (AEB071) is a pan-PKC inhibitor in clinical trials (Buder et al., 2013; Chen et 
al., 2014). The resistance induced by PMA in H3122 and MGH006 was reversed by 
sotrastaurin, consistent with a PKC-dependent phenotype (Figure 6D, G). Furthermore, 
H3122 cells ectopically expressing P2Y receptors were sensitive to the combination of 
crizotinib and sotrastaurin (Figure 6H). The effect appeared specific for P2Y receptors, as 
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this combination did not impact resistance conferred by RAF1 (another resistance driver 
identified from the study; Figure 6H).
As PKCδ is not included in the CCSB-Broad ORF library, we tested whether overexpression 
of PKCδ (encoded by PRKCD) is sufficient to confer resistance to ALK inhibition in H3122. 
We observed that overexpression of PKCδ alone is not sufficient to induce resistance to 
TAE684 in our assay, suggesting that other PKC isoforms activated by PMA and inhibited 
by sotrastaurin may be driving the observed resistance (Figure S4). Of note, the initial 
screening study also identified another PKC isoform, PKCε (encoded by PRKCE), as 
sufficient to drive resistance to ALK inhibition in H3122 (Figure 2C).
Enrichment of gene signatures associated with resistance drivers in ALK inhibitor-
resistant tumors compared to treatment-naive controls
We next asked whether identified resistance drivers and associated pathways might play a 
role in clinical resistance to ALK inhibition. We used RNAseq to generate gene expression 
profiles from a cohort of ALK-rearranged lung tumors with acquired resistance to crizotinib 
and from treatment-naïve ALK-rearranged controls (Table 1). Specimen DFCI76 harbors a 
secondary EML4-ALK mutation associated with crizotinib resistance (Sasaki et al., 2011); 
all other tumors lacked secondary ALK mutations (and activating EGFR or KRAS 
mutations), suggesting alternative resistance mechanisms. We used single-sample Gene Set 
Enrichment Analysis (ssGSEA) to query gene expression signatures for enrichment in 
resistant tumors compared to controls (Barbie et al., 2009; Konieczkowski et al., 2014; 
Subramanian et al., 2005). A total of 286 oncogenic gene signatures were evaluated, 
including 189 from the Molecular Signatures database (Liberzon et al., 2011). These include 
signatures associated with activation of a subset of resistance drivers/pathways identified 
from our screen, along with a P2Y signature we derived from overexpression of P2Y 
receptors in H3122 (Experimental Procedures; Figure 7A).
Among the gene signatures enriched in resistant tumors compared to controls (with FDR 
≤0.2) were 5 signatures associated with resistance drivers/pathways identified from our 
functional study. Two of these were independent EGFR signatures (Creighton et al., 2006; 
Gatza et al., 2010; Gatza et al., 2014), consistent with prior reports of an association 
between EGFR activation and clinical resistance to ALK inhibition (Figure 7B). We also 
observed enrichment of HER2 and RAF1 signatures in resistant tumors, consistent with our 
findings of NRG1 (which activates HER2/HER3) and RAF1 as strong drivers of resistance 
to ALK inhibition (Figure 4, 5) (Creighton et al., 2006; Gatza et al., 2010; Gatza et al., 
2014). Finally, the P2Y signature we identified in H3122 cells overexpressing P2Y receptors 
was also enriched in crizotinib-resistant tumors (Figure 7B, C; Figure S5; Table S1, S2). 
These findings suggest activation of transcriptional states associated with EGFR, HER2, 
P2Y, and RAF1 in crizotinib-resistant tumors and likely reflect underlying biological 
relationships between these pathways. Examination of expanded patient cohorts will be 
necessary to confirm these findings. Of note, many genes and pathways identified from our 
functional studies as resistance drivers are not represented among gene signatures used for 
ssGSEA analysis, limiting a computational assessment of those genes/pathways in resistant 
tumors compared to controls.
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Given these results, we asked if transcripts encoding EGFR, HER2, RAF1, or P2Y receptors 
were increased in resistant tumors. Among these, expression of both P2RY6 and P2RY2 was 
significantly increased in crizotinib-resistant tumors compared to treatment-naïve controls 
(p=0.021 and 0.033, respectively; Figure 7D, E). This observation provides further support 
for activation of a P2Y gene signature in resistant tumors.
Expression signatures associated with PKC activation were not represented in the reference 
collection of gene signatures used for the ssGSEA analyses described above. Therefore, we 
queried tumor expression profiles against the compendium of expression signatures 
associated with chemical perturbations in the Connectivity Map (CMap) that included PKC 
agonists (Experimental Procedures; Table S3). Among the ALK-rearranged tumors were a 
relapsed post-ceritinib (DFCI133) and a pre-ceritinib (DFCI107) specimen obtained from a 
single patient who previously experienced disease progression on crizotinib (Table 1). 
Among >3200 compounds profiled in CMap, the top 3 chemical signatures most similar to 
DFCI133 (compared to DFCI107) were PKC agonists (Table S4). Although limited to a 
single patient, this preliminary observation is suggestive of PKC activation in a tumor with 
acquired resistance to ceritinib, consistent with our functional data. However, we did not 
identify a connection between gene signatures induced by PKC agonists and the entire 
cohort of unmatched resistant ALK-rearranged tumors compared to treatment-naïve 
controls.
Discussion
Patients with advanced ALK-rearranged lung cancers are treated with ALK inhibitors 
including crizotinib and newer second-generation inhibitors such as ceritinib or alectinib 
(Kwak et al., 2010; Shaw et al., 2014). As responses to these agents are generally short-
lived, an understanding of the mechanisms leading to drug resistance is essential for the 
design of therapeutic strategies to improve efficacy. Here we present findings from a 
systematic large-scale functional study of resistance to ALK inhibition in ALK-rearranged 
lung cancer. At least 10 of the 54 ORFs identified as potential drivers of resistance to ALK 
inhibition represent pathways and proteins previously implicated in clinical resistance to 
targeted therapies in lung cancer. These include the EGFR pathway (represented by 5 EGF 
ligands identified from our study), MET activation (represented by HGF), SRC-related 
kinases (represented by FGR, LCK, and LYN), and the AXL receptor tyrosine kinase 
(Crystal et al., 2014; Engelman et al., 2007; Katayama et al., 2012; Zhang et al., 2012). 
These findings underscore the capacity of a functional genomic approach using appropriate 
cell line model systems to identify clinically-relevant resistance mechanisms.
Our results provide a landscape of genes capable of driving resistance to ALK inhibition and 
offer multiple insights about resistance pathways. A subset of the identified resistance 
drivers defines a signal transduction network from cell membrane to nucleus, including 
growth factors, receptor tyrosine kinases, adapter proteins, serine-threonine kinases, and 
transcription factors and DNA/RNA binding proteins. Our findings suggest that increased 
expression of individual genes representing multiple nodes of this signal transduction 
network is sufficient to drive resistance to ALK inhibition in an ALK-dependent lung cancer 
cell system. We demonstrate a subset of these findings is also relevant in the context of 
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resistance to EGFR inhibitors in EGFR-mutant lung cancer. In particular, a number of 
growth factors, kinases, and adapter proteins identified as ALK resistance drivers that re-
activate MEK/ERK and/or PI3K signaling in H3122 also drive resistance to EGFR 
inhibition in EGFR-mutant lines. This finding highlights the fundamental role of these 
pathways in mediating the oncogenic effects of aberrant EGFR and ALK signaling.
In total, approximately half of the resistance drivers identified from our study reactivate 
MEK/ERK and/or PI3K signaling in H3122. Not all resistance drivers impact these 
pathways, however, suggesting alternative bypass mechanisms. Members of the P2Y family 
of purinergic receptors and downstream PKC activation represent previously unrecognized 
mediators of resistance to ALK inhibition. Overexpression of P2Y receptors did not impact 
MEK/ERK or PI3K signaling in our assays (Figure 3A, B; Figure 6C). However, there are 
reports suggesting a role for P2Y receptors in EGFR transactivation and MAP kinase 
pathway activation in other cell systems (Buvinic et al., 2007; Kehasse et al., 2013; Peterson 
et al., 2010; Ratchford et al., 2010; Sham et al., 2013; Tamaishi et al., 2011). The observed 
enrichment of gene signatures associated with EGFR, HER2, RAF1, and P2Y in crizotinib-
resistant tumors may hint at shared resistance-associated transcriptional targets downstream 
of these pathways.
P2Y receptors mediate resistance at least in part through PKC activation. We demonstrate 
that PKC activation alone is sufficient to induce resistance to ALK inhibition and is 
overcome with combined ALK and PKC inhibition. A recent study of resistance to the BCR-
ABL inhibitor imatinib in chronic myeloid leukemia revealed that up-regulation of PKCη 
confers resistance by activation of RAF1 and MEK/ERK signaling (Ma et al., 2014). Further 
work will be required to characterize the PKC isoforms driving PKC-mediated resistance in 
our study. In addition, larger tumor cohorts will be necessary to determine the prevalence of 
P2Y and/or PKC activation in clinical resistance to ALK inhibition.
In comparing resistance profiles between crizotinib and second-generation ALK inhibitors 
in H3122 cells, we identify HGF (which activates MET), AXL, and MST1R (also known as 
RON) as 3 potential mechanisms of resistance to a second-generation ALK inhibitor that do 
not impact sensitivity to crizotinib. As noted above, both increased MET and AXL 
expression has been implicated in clinical resistance to EGFR inhibitors in EGFR-mutant 
lung cancer (Engelman et al., 2007; Zhang et al., 2012). As crizotinib has activity against 
MET, AXL, and MST1R in addition to ALK, our findings suggest that crizotinib may 
additionally target at least 3 receptor tyrosine kinases that are potential drivers of resistance 
to ALK inhibition in H3122. This observation may have therapeutic implications if first-line 
treatment of advanced ALK-rearranged NSCLC shifts from crizotinib to more selective 
second-generation inhibitors that lack activity against AXL, MST1R, and MET. Conversely, 
recent work has shown that the second-generation ALK inhibitor ceritinib has activity 
against IGF-1R (in addition to ALK), which is a potential mechanism of resistance to 
crizotinib (Lovly et al., 2014). Thus both crizotinib and second-generation ALK inhibitors 
may simultaneously target distinct potential resistance drivers in addition to ALK itself.
Our findings nominate several possible agents (including inhibitors of EGFR, HER2/HER3, 
or PKC) that might in principle be combined with ALK inhibition to overcome or delay a 
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range of resistance mechanisms. However, an emerging theme from this and other 
comprehensive resistance studies is that activation of multiple pathways may contribute to 
the drug resistance phenotype (Huang et al., 2012; Johannessen et al., 2013). This poses a 
significant therapeutic challenge, as it may not be feasible to target all possible resistance 
pathways. The potential for “resistance heterogeneity” in the clinical arena may complicate 
identification of an optimal treatment strategy for individuals whose tumors acquire 
resistance to targeted therapies. Repeat biopsy at disease progression may provide an 
opportunity for characterization of resistant tumors to prioritize combinations for individual 
patients, but multiple resistance mechanisms within the same tumor could limit therapeutic 
efficacy (Gerlinger et al., 2012). Detailed molecular characterization of patient-derived 
tumors might determine the frequency at which specific resistance mechanisms occur in 
patients, potentially enabling prioritization of high-order therapeutic combinations for 
clinical trial design.
In the future, therapeutic disruption of resistance-associated transcriptional states may 
provide an alternative to targeting of individual upstream signaling pathways, inasmuch as 
such pathways might converge onto shared transcriptional outputs that drive tumor growth 
in drug-resistant states. Theoretically, this might be achieved by incorporation of chromatin-
modifying agents as part of an ALK-directed treatment strategy. Such an approach that does 
not rely solely on inhibition of upstream signaling proteins susceptible to bypass might lead 
to more durable responses to targeted therapies.
Experimental Procedures
Cell Lines and Reagents
H3122 cells were obtained from the National Cancer Institute. Generation of ceritinib-
resistant H3122 cells is described in the Supplemental Experimental Procedures. H2228, 
HCC827, and HCC4006 were purchased from the American Type Culture Collection 
(ATCC). PC-9 cells were obtained from Public Health England, and KELLY neuroblastoma 
cells were obtained from Sigma-Aldrich. Cells were maintained in RPMI-1640 (Cellgro) 
with 10% fetal bovine serum (Gemini Bioproducts) and penicillin (100 units/mL) / 
streptomycin (100 µg/mL; Cellgro). MGH006 cells have been previously reported and were 
maintained in DMEM (Cellgro) with 10% fetal bovine serum, penicillin, and streptomycin 
(Sequist et al., 2010). All cell lines were tested to confirm the absence of mycoplasma 
contamination. Crizotinib, TAE684, ceritinib, erlotinib, lapatinib, and sotrastaurin were 
purchased from Selleck Chemicals. Blasticidin was obtained from Life Technologies. 
Phorbol 12-myristate 13-acetate (PMA) was purchased from Santa Cruz Biotechnology.
Screening of the CCSB-Broad Lentiviral Expression Library
The Center for Cancer Systems Biology (CCSB)-Broad Lentiviral Expression library has 
been previously described (Yang et al., 2011). Additional information is included in the 
Supplemental Experimental Procedures. H3122 cells were seeded in white clear-bottom 
384-well microtiter plates at 1500 cells per well using a Multidrop Combi (Thermo-
Scientific). The next day, cells were spin-infected with the expression library (or L1152R 
EML4-ALK as a positive control) in the presence of 4 ug/mL polybrene at 2250 rpm for 30 
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minutes at 37°C. Cells were infected in 7 replicates. Virus was removed after 24 hours and 
replaced with standard growth media (containing 12 ug/mL blasticidin for one replicate). 
After an additional 48 hours, the remaining 6 replicates of ORF-expressing cells were 
treated with 0.01% DMSO (drug vehicle), 1 µM crizotinib, or 30 nM TAE684 (2 replicates 
each). Lentiviral infection, media change, and drug addition were all performed with 
robotics. Following 5 days of drug exposure, cell viability was determined using the Cell 
Titer-Glo luminescent assay (Promega) according to the manufacturer’s instructions. 
Luminescence was measured with an EnVision Multilabel Reader (Perkin-Elmer). 
Screening of the entire CCSB-Broad Lentiviral Expression library (which is arrayed in 
forty-seven 384-well plates) was performed in 7 batches. Identification and validation of 
candidate resistance ORFs (and associated statistical analyses) are described in the 
Supplemental Experimental Procedures.
Antibodies and immunoblotting
Cells were lysed in 50 mM HEPES (pH 7.5), 1% Triton X-100, 10% glycerol, 150 mM 
NaCl, 2 mM EDTA, and 10 mM NaF with protease inhibitors (Roche) and phosphatase 
inhibitors (Calbiochem). Lysates were fractionated by SDS-polyacrylamide gel 
electrophoresis and transferred to nitrocellulose membranes using the iBlot system (Life 
Technologies). Two-color immunoblotting was performed using LI-COR reagents (Odyssey 
Blocking Buffer and IRDye 800CW and IRDye 680RD secondary antibodies) according to 
the manufacturer’s instructions (LI-COR Biosciences). Fluorescence detection was 
performed using an Odyssey CLx Infrared Imaging System, and quantitation was performed 
using Image Studio software (LI-COR). Antibodies against ALK (#3791), AKT (#2920), 
phospho-AKT (Ser 473; #4060), EGFR (#2239), phospho-EGFR (Tyr 1068; #3777), PKCδ 
(#9616), and phospho-PKCδ (Tyr 311; #2055) were obtained from Cell Signaling. ERK2 
antibody (sc-154) was purchased from Santa Cruz Biotechnology. Antibodies against 
phospho-ERK1/ERK2 (Thr 185/Tyr 187; #M8159) and vinculin (#V9131) were obtained 
from Sigma. V5 antibody (#R960-25) was obtained from Life Technologies. In-cell Western 
blotting is described in the Supplemental Experimental Procedures.
Colony-formation assays
H3122 cells were seeded in 12-well plates at a density of 10–20,000 cells per well. The 
following day, cells were spin-infected with lentivirus harboring the indicated ORFs in the 
presence of 4 µg/mL polybrene. Virus was removed after 24 hours and replaced with 
standard growth media. After an additional 24–48 hours, cells were treated with drug or 
DMSO as indicated. Cells were exposed to drug or DMSO for 14–21 days, with media 
change and fresh drug addition every 3 days. Cells were fixed with 4% formaldehyde and 
stained with 0.5% crystal violet. Cells were photographed using a Leica microscope and 
imaging software. Quantification of crystal violet uptake for each sample was determined by 
de-staining cells with 10% acetic acid and measurement of absorbance at 595 nm using a 
SpectraMax 190 instrument (Molecular Devices).
Whole-transcriptome sequencing (RNAseq)
Patients with ALK-rearranged NSCLC were identified from the Lowe Center for Thoracic 
Oncology at Dana-Farber Cancer Institute. Tumor samples were obtained under an 
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institutional IRB-approved protocol, and all participating patients provided written informed 
consent. Total RNA was extracted from fresh frozen tumor specimens using TRIzol (Life 
Technologies) according to the manufacturer’s instructions. The presence of the EML4-ALK 
fusion transcript was confirmed by RT-PCR for each tumor.
We also prepared total RNA from H3122 cells expressing P2Y receptors for RNAseq. 
Parental H3122 cells or H3122 expressing ectopic Lac Z, P2Y1, or P2Y2 were exposed to 
100 nM TAE684 for 12 hours. (Experimental samples were H3122 cells expressing P2Y1 or 
P2Y2; control samples were parental H3122 and H3122 cells expressing Lac Z.) Total RNA 
was extracted using the RNeasy kit (Qiagen) with on-column DNase treatment.
cDNA libraries were generated for tumor and cell line samples using the TruSeq Sample 
Preparation kit (Illumina) with polyA selection according to the manufacturer’s protocol 
(Revision A 2010). Libraries were pooled using indexed adapters for multiplexing. Pooled 
libraries were normalized to 2 nM and denatured using 0.2 N NaOH prior to sequencing. 
Flowcell cluster amplification and sequencing were performed according to the 
manufacturer’s protocols using either the HiSeq 2000 or HiSeq 2500 to a depth of 45–50 
million reads per sample (paired-end with 76 base pair reads).
Data was analyzed using the Broad Picard Pipeline which includes de-multiplexing and data 
aggregation. Reads were mapped to the reference human genome (hg19) using TopHat 
1.4.1. Expression levels for each gene were denoted as RPKM values (reads per kilobase of 
transcript per million mapped reads) determined using Cufflinks 2.0.2. Genes that were not 
expressed in any patient-derived tumor samples (RPKM=0) were removed from the tumor 
dataset; genes not expressed in the cell line samples were removed from the cell line dataset. 
Differential transcript expression was determined with the signal-to-noise test statistic with 
standard deviation at least 20% of the class mean. A description of the methods used to 
analyze RNAseq gene expression data is provided in the Supplemental Experimental 
Procedures.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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□ Multiple genes and pathways are sufficient to drive resistance to ALK 
inhibition
□ A subset also confer resistance to EGFR inhibition in EGFR-mutant lung 
cancer
□ P2Y receptors mediate ALK inhibitor resistance in part via protein kinase C
□ EGFR, HER2, and P2Y gene signatures are enriched in crizotinib-resistant 
tumors
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ALK inhibitors including crizotinib and ceritinib have transformed the treatment of 
advanced ALK-rearranged NSCLC. Unfortunately, responses to these agents are not 
durable, motivating efforts to characterize resistance mechanisms that inform future 
combinatorial treatment strategies. We assayed over 12,000 genes for the capacity to 
drive resistance to ALK inhibition when overexpressed in ALK-dependent lung cancer 
cells. Along with known resistance pathways, we identify additional resistance drivers 
including several P2Y purinergic receptors acting in part via protein kinase C (PKC). 
Collectively, our findings identify a spectrum of mechanisms sufficient to confer 
resistance to ALK inhibitors in NSCLC and suggest a role for P2Y receptors and PKC 
signaling in resistance to these agents.
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A large-scale ORF screen identifies candidate mediators of resistance to ALK inhibition. A. 
Overview of the experimental approach. H3122 cells were spin-infected with the CCSB-
Broad lentiviral expression library. ORF-expressing cells were then treated with crizotinib, 
TAE684, DMSO, or blasticidin as indicated. Cell viability was determined after 5 days of 
drug exposure using Cell Titer-Glo. B. Growth curves for H3122 cells ectopically 
expressing Lac Z, wild-type (WT) EML4-ALK, or L1152R EML4-ALK and exposed to 
crizotinib or TAE684 at varying concentrations for 5 days. Mean and standard error of 3 
replicates are shown. Results are representative of 3 independent experiments. C. Cell 
viability (expressed as raw luminescence values) for all assayed ORFs in the presence or 
absence of drug. D. Percent (%) viability z-scores in the presence of crizotinib or TAE684 
for each experimental ORF. % viability z-scores are defined as the normalized ratio of cell 
viability in drug to cell viability in drug vehicle (DMSO). % viability z-scores for replicates 
of the L1152R EML4-ALK positive control are shown in red. Experimental ORFs 
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associated with a % viability z-score ≥3 were selected as candidate mediators of resistance. 
See also Figure S1.
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Validation of candidate ORFs as drivers of resistance to ALK inhibition in H3122. A. 
Summary of initial screening and validation studies in H3122. 61 experimental ORFs 
(representing 54 genes) with a percent (%) viability z-score ≥3 for either drug were 
validated in H3122 by assessing viability of ORF-expressing cells in varying concentrations 
of crizotinib and TAE684. SD, standard deviation; AUC, area under the curve. B. 
Classification of the 54 genes validated as mediators of resistance in H3122. C. Heat map 
displaying normalized area under the curve (AUC) for validated drivers of resistance to 
crizotinib (CRZ) and TAE684 (TAE) in H3122 compared to negative controls (left). 
GPCRs, G-protein coupled receptors; GEFs, guanine nucleotide exchange factors. D. 
Growth curves from H3122 cells expressing MST1R, AXL, and HGF in crizotinib or 
TAE684. Mean and standard error of 4 replicates are shown. Growth curves of H3122 cells 
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expressing negative control ORFs (BFP and HcRed) and the L1152R EML4-ALK positive 
control are shown for comparison. See also Figure S2.
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A subset of validated resistance ORFs reactivate MEK/ERK or PI3K signaling. Protein 
lysates were prepared from ORF-expressing H3122 cells after treatment with 100 nM 
TAE684 for 8 hours. Immunoblotting was performed with antibodies against ERK2, 
phospho-ERK1/ERK2, AKT, and phospho-AKT. Fluorescence signal intensity for protein 
bands was quantitated. A. Ratio of pAKT/AKT immunostaining was determined for each 
ORF and normalized to mean pAKT/AKT determined from 13 negative controls (left). Fold-
increase in pAKT/AKT relative to controls is shown, with the red horizontal line 
representing mean pAKT/AKT from controls. B. As in A, except with pERK/ERK. GPCRs, 
G-protein coupled receptors; GEFs, guanine nucleotide exchange factors. C. Venn diagram 
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demonstrating overlap between ORFs reactivating AKT or ERK. Resistance ORFs 
associated with a pAKT/AKT or pERK/ERK ratio ≥2.5 standard deviations above the mean 
(as determined from the negative controls) were designated as ORFs reactivating AKT or 
ERK in the presence of TAE684, respectively. 28 of 54 resistance ORFs (52%) met this 
criteria for AKT or ERK; 14 of these 28 ORFs were associated with reactivation of both 
AKT and ERK and are indicated in the shaded box.
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A subset of resistance ORFs identified in H3122 also drive resistance to targeted therapies in 
other lung cancer cell systems. Heat map displaying normalized area under the curve (AUC) 
for validated drivers of resistance to crizotinib (CRZ) and TAE684 (TAE) in H3122 
compared to negative controls (left) as in Figure 2C. Normalized percent viability for ORF-
expressing cells in the indicated doses of CRZ or TAE (for MGH006) or erlotinib (ERL; for 
HCC827, HCC4006, and PC-9) are shown. Relative expression of each ectopic experimental 
ORF in each cell line is shown in Figure S3. Of note, we were unable to demonstrate ectopic 
expression of L1152R EML4-ALK in MGH006 (data not shown), and no effect of this 
positive control ORF was therefore observed on resistance to ALK inhibition in MGH006. 
GPCRs, G-protein coupled receptors; GEFs, guanine nucleotide exchange factors. See also 
Figure S3.
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Neuregulin-1 (NRG1) drives resistance to ALK inhibition in ALK-dependent NSCLC cell 
lines but not in an ALK-dependent neuroblastoma cell line (KELLY). A. H2228, H3122, 
and KELLY cells were exposed to increasing concentrations of NRG1 at the indicated doses 
of TAE684 for 5 days. Cell viability was determined with Cell Titer-Glo. Mean and standard 
error of 3 replicates are shown. B. H2228, H3122, and KELLY cells were exposed to 200 
nM TAE684 in the presence or absence of 50 ng/mL NRG1 for 6 hours. Immunoblotting of 
cell lysates was performed with the indicated antibodies. C. H3122 and MGH006 cells were 
exposed to 50 ng/mL NRG1 with or without 1 µM lapatinib in varying concentrations of 
TAE684 for 5 days. Cell viability was determined as in A. Mean and standard error of 3 
replicates are shown. D. H3122 and MGH006 cells were exposed to combinations of 200 
nM TAE684, 50 ng/mL NRG1, and 1 µM lapatinib for 6 hours. Immunoblotting was 
performed using the indicated antibodies.
Wilson et al. Page 26














P2Y receptors drive resistance to ALK Inhibition in H3122 via a PKC-dependent 
mechanism. A. H3122 expressing Lac Z, P2Y1, P2Y2, or P2Y6 were exposed to DMSO for 
14 days or 0.3 µM crizotinib (CRZ) or 15 nM ceritinib (CER) for 21 days followed by 
staining with crystal violet. Media was changed with fresh drug addition every 3 days. B. 
Quantitation of crystal violet uptake by ORF-expressing cells exposed to crizotinib (CRZ) or 
ceritinib (CER) normalized to Lac Z. Mean and standard error are shown for 6 (CRZ) or 4 
(CER) independent experiments of 3 replicates each. C. Lysates from H3122 cells 
overexpressing Lac Z, P2Y1, or P2Y2 were subjected to fractionation and immunoblotting 
with the indicated antibodies. D. H3122 and MGH006 cells were treated with the indicated 
compounds [1 µM PMA, 0.3 µM sotrastaurin (SOT), or combination] in varying 
concentrations of ceritinib. Cell viability was determined after 5 days. Mean and standard 
error of 3 replicates are shown. Results are representative of 4 independent experiments with 
ceritinib or TAE684. E. Cell viability of H3122 and MGH006 treated with 1 µM PMA 
(normalized to H3122 or MGH006 treated with DMSO as 100%). Mean and standard error 
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of 3 replicates are shown. The experiment was performed 4 times. F. Lysates from parental 
(P) or ceritinib-resistant (R1, R2) H3122 cells were subjected to fractionation and 
immunoblotting with the indicated antibodies. G. Lysates from H3122 and MGH006 cells 
treated with 1 µM PMA in the presence or absence of 0.3 µM sotrastaurin (SOT) were 
fractionated. Immunoblotting was performed with the indicated antibodies. H. As in A, 
except ORF-expressing cells were exposed to the indicated compounds for 20 days. Results 
are representative of 3 independent experiments. See also Figure S4.
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Enrichment of gene expression signatures in ALK inhibitor-resistant ALK-positive lung 
tumors compared to treatment-naive ALK-positive lung tumors. A. Overview of the 
experimental approach to generate a P2Y gene signature in vitro and to then query this 
signature (along with 285 additional gene signatures) for enrichment in ALK inhibitor-
resistant ALK-rearranged lung tumors compared to treatment-naïve controls. ssGSEA, 
single-sample gene set enrichment analysis. B. Identification of 5 gene signatures enriched 
in resistant tumors compared to treatment-naïve using ssGSEA. Two independent EGFR 
signatures were identified; EGFR (1) and EGFR (2) are reported in Creighton et al., 2006 
and Gatza et al., 2010, respectively. Index values range from −1 to 1 and refer to correlation 
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between the indicated gene set and enrichment in resistant compared to treatment-naïve 
tumors (see Experimental Procedures). Rank positions according to index value for gene 
signatures (out of 286 total signatures) are indicated. P-values were determined using a 
permutation test with 1000 permutations of the indicated profile (see Experimental 
Procedures). C. Gene set enrichment analysis reveals that 76 of the top 200 genes up-
regulated in the P2Y gene signature (P2Y_UP) are also up-regulated in ALK inhibitor-
resistant tumors compared to treatment-naive tumors. NES, normalized enrichment score; 
FDR, false discovery rate; FWER p-value, family-wise error rate p-value. D. Expression of 
P2RY6 from RNA-seq of treatment-naive (”pre-treatment”) and ALK inhibitor-resistant 
(”resistant”) tumors. Expression is indicated in ‘reads per kilobase per million reads’ 
(RPKM). Mean and standard error are shown. ALK inhibitor-resistant tumors obtained from 
the same patient are indicated in red or blue. P-value determined by one-tailed Mann-
Whitney nonparametric test. E. As in D, except for P2RY2. See also Figure S5 and Tables 
S1–S4.
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Table 1
Clinical Characteristics of Patient-Derived Tumors
Sample Age Gender Biopsy Site Status Response PFS (Months) ALK Mutation
DFCI76 63 F Lymph Node R PR 2.8 Yes (L1152R)
DFCI89 * 46 M Lung Core R PR 14 No
DFCI96 * 46 M Pleural Fluid R PR 14 No
DFCI107 ** 41 F Liver Metastasis R PR 6.4 No
DFCI133 ** 41 F Liver Metastasis R (ceritinib) SD 7.4 No
DFCI147 61 M Lung Core R PR 9.8 No
DFCI152 67 F Lung Core R PR 33.5 No
DFCI171 58 M Pleural Fluid R PR 3.4 No
DFCI59 40 M Lymph Node TN N/A N/A No
DFCI66 63 F Lymph Node TN N/A N/A No
DFCI69 46 F Lymph Node TN N/A N/A No
DFCI125 58 M Pleural Fluid TN N/A N/A No
DFCI142 47 M Pleural Fluid TN N/A N/A No
Tumor samples derived from the same patient are indicated with * or **.
R = resistant to crizotinib. DFCI133 was obtained after development of resistance first to crizotinib followed by ceritinib. TN = treatment-naïve.
PR, SD = partial response, stable disease (respectively) by RECIST criteria.
PFS = progression-free survival
Tumors harboring secondary ALK mutations known to be associated with crizotinib resistance are indicated under “ALK Mutation”.
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